Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15318993 | 1.00 | CSNK2A2 (0.48) | CSNK2A2CSNK2BCSNK2A1KMT2AMEN1 | |
| SCHEMBL43717 | 1.00 | CSNK2A2 (0.48) | CSNK2A2CSNK2BCSNK2A1KMT2AMEN1 | |
| SCHEMBL28981240 | 0.98 | CSNK2A2 (0.47) | CSNK2A2CSNK2BCSNK2A1KMT2AMEN1 | |
| Mercaptopropionic Acid SCHEMBL4955336 | 0.85 | PTGS1 (0.39) | CSNK2A2CSNK2BCSNK2A1KMT2AMEN1 | |
| SCHEMBL6047333 | 0.85 | KMT2A (0.42) | CSNK2A2CSNK2BCSNK2A1KMT2AMEN1 | |
| SCHEMBL15391718 | 0.82 | PTGS1 (0.51) | CSNK2A2CSNK2BCSNK2A1KDM4ELMNA | |
| SCHEMBL22241544 | 0.81 | LMNA (0.36) | CSNK2A2CSNK2BCSNK2A1KMT2AMEN1 | |
| SCHEMBL2611102 | 0.81 | LMNA (0.36) | CSNK2A2CSNK2BCSNK2A1KMT2AMEN1 | |
| SCHEMBL28844372 | 0.80 | TSHR (0.39) | CSNK2A2CSNK2BCSNK2A1KMT2AMEN1 | |
| SCHEMBL321357 | 0.79 | LMNA (0.35) | CSNK2A2CSNK2BCSNK2A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024091437-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-2451839-B1 | METHOD FOR THE PRODUCTION OF VARIABLE DOMAINS | ABLYNX NV (BE) | 2020-04-22 | — | — | EP | disclosed |
| US-9150640-B2 | Method for the production of variable domains | ABLYNX N.V. (BE) | 2015-10-06 | — | — | US | disclosed |
| US-9012567-B2 | Supramolecular polymers and compositions containing said polymers | RHODIA OPERATIONS (FR) | 2015-04-21 | — | — | US | disclosed |
| US-20150023963-A1 | METHOD FOR THE PRODUCTION OF VARIABLE DOMAINS | ABLYNX N.V. (BE) | 2015-01-22 | — | — | US | disclosed |
| WO-2015000585-A1 | MUTEINS OF CYTOKINES OF THE GAMMA-CHAIN RECEPTOR FAMILY CONJUGATED TO A NON-PROTEIN GROUP | SEBALD WALTER (DE) | 2015-01-08 | — | — | WO | disclosed |
| US-20140073778-A9 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20130184454-A1 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| EP-2524229-A1 | METHOD FOR PREPARING POLYBIOTINYLATED COMPOUNDS | Biomérieux (FR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086321-A1 | METHOD FOR PREPARING POLYBIOTINYLATED COMPOUNDS | bioMérieux (FR) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011003622-A1 | METHOD FOR THE PRODUCTION OF VARIABLE DOMAINS | ABLYNX N.V. (BE) | 2011-01-13 | — | — | WO | disclosed |
| US-5773271-A | Compounds from biopolymers and effector substances which are linked via optically active amino acid derivatives, processes for the preparation thereof and the use thereof | BEHRING DIAGNOSTICS GMBH (DE) | 1998-06-30 | — | — | US | disclosed |
| US-5744315-A | Compounds from biopolymers and effector substances which are linked via optically active amino acid derivatives, processes for the preparation thereof and the use thereof | BEHRING DIAGNOSTICS GMBH (DE) | 1998-04-28 | — | — | US | disclosed |
| US-5484722-A | Biopolymer and effector substance conjugates, process for the preparation thereof and their use | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1996-01-16 | — | — | US | disclosed |
| US-5321142-A | Compounds from biopolymers and effector substances which are linked via optically active amino acid derivatives, processes for the preparation thereof and the use thereof | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1994-06-14 | — | — | US | disclosed |
| US-5030620-A | Anticarcinogenic and antitumor agents | OMNICHEM (BE) | 1991-07-09 | — | — | US | disclosed |
| US-4828831-A | ANTICANCER | OMNICHEM (BE) | 1989-05-09 | — | — | US | disclosed |
| EP-0308983-A2 | NMR imaging with Mn(II) coordination compositions | SALUTAR, INC. (US) | 1989-03-29 | — | — | EP | disclosed |
| EP-0232693-A2 | Conjugates of vinblastine and its derivatives, process for their preparation and pharmaceutical compositions containing them | LA REGION WALLONNE (BE) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | ADCY3, ADCY8, ADCY7 | CSNK2A2 3074/4885CSNK2B 3290/4885CSNK2A1 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.